Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms

Thoracoabdominal Aortic Aneurysm Clinical Trial

Official title:

Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03113383
• Other study ID #: 161627
• Status: Terminated
• Phase: N/A
• Start date: August 18, 2017
• Est. completion date: October 6, 2021

Study information

• Verified date: October 2022
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the clinical investigation is to assess the use of the the Visceral Manifold Thoracoabdominal Aortic Aneurysms (VTAAA) stent graft system to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety (i.e. freedom from major adverse events (MAE) at 30 days) and preliminary effectiveness (i.e., treatment success and technical success) of the device (i.e., the proportion of treatment group subjects that achieve and maintain treatment success at one year).

Description:

The primary purpose of this study is to evaluate the safety of this device as there are no or very limited devices and clinical options available for this patient population. The primary safety endpoint of this study is safety freedom from major adverse events (MAE) at 30 days or during hospitalization if this exceeds 30 days. Major adverse events include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, and stroke. The primary safety endpoint will be analyzed to determine statistical significance when compared to a target performance goal. A literature review of outcomes of open surgical repair was used to create the performance goal as there is not a comparable endovascular option to use for analysis. The performance goal was selected based on the range of subjects experiencing a major adverse event at 30 days. The range was calculated based on assumptions of the minimum and maximum number of subjects experiencing at least one MAE in the historical open surgical repair group . Based on the literature reviewed and the above assumptions the range of subjects experiencing at least one MAE in the open surgical repair group is 30.5% to 77.4%. The primary effectiveness endpoint is the proportion of the study subjects with treatment success at 1 year. The data will be presented as quality outcomes with the number of study subjects with treatment success compared to the overall patient population. Additionally, data outcomes from this study will be entered into a common vascular database so that data can be pooled with other PS-IDEs. This would provide consistent reporting across the PS-IDEs. Additionally, the PS-IDEs will be evaluating the same device and endpoints to allow for a pool-ability of data across the sites. The pooled data will be separated into two separate study arms: primary study arm and expanded selection arm.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: October 6, 2021
• Est. primary completion date: March 2, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Primary Arm

General Inclusion Criteria:

• A patient may be entered into the study if the patient has at least one of the

following:

• An aneurysm with a maximum diameter of greater than or equal to 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
• Aneurysm with a history of growth greater than or equal to 0.5 cm in 6 months
• Saccular aneurysm deemed at significant risk for rupture
• Symptomatic aneurysm greater than 4.5 cm
• Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
• Proximal landing zone for the thoracic bifurcation stent graft that has:
• Greater than or equal to 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA) diameter in the range of 26-42 mm
• Adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold
• Minimum branch vessel diameter greater than 5 mm
• Iliac artery or aortic distal fixation site, including both native tissue and previously placed graft, greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm
• Age: greater than or equal to 18 years old
• Life expectancy: greater than 1 year

Exclusion Criteria:

• Patient is a good candidate for and elects for open surgical repair
• Can be treated in accordance with the instructions for use with a legally marketed endovascular device
• Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
• Unwilling to comply with the follow-up schedule
• Inability or refusal to give informed consent
• Urgent or emergent presentation
• Patient is pregnant or breastfeeding
• Patient has a contained rupture
• Patient has a ruptured aneurysm
• Patient has a dissection in the portion of the aorta intended to be treated
• Obstructive stenting of any or all of the visceral vessels
• Poor performance status including two major system failures (including but not limited to cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular) Medical Exclusion Criteria
• Known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel: Titanium) polyester, platinum-iridium, polytetrafluoroethylene (PTFE), platinum, gold, polyethylene, or stainless steel.
• Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
• Uncorrectable coagulopathy
• Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
• Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned less than 30 days of the endovascular repair
• Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
• Systemic or local infection that may increase the risk of endovascular graft infection
• Baseline creatinine greater than or equal to 2.0 mg/dL
• History of connective tissue disorders (e.g., Marfan Syndrome in the primary arm only, not applicable for patients in the the expanded access arm, Ehler's Danlos Syndrome)
• Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in a landing zone that expands beyond any limits of the previously placed graft material

Anatomical exclusion criteria:

• Minimum branch vessel diameter less than 5 mm
• Thrombus or excessive calcification in the proximal aortic neck
• Anatomy that would not allow maintenance of at least one patent hypogastric artery
• Anatomy that would not allow primary or assisted patency of the left subclavian artery Expanded Selection Arm Inclusion Criteria
• Patient that meets the criteria for inclusion in the primary study arm but has one or

more of the following criteria which would exclude them from the primary study arm:

• Minimum branch vessel diameters <less than 5mm
• Urgent or emergent presentation
• Patient has a contained rupture
• Patient has a ruptured aneurysm
• Patient has a type B dissection (subacute or chronic) in the portion of the aorta intended to be treated
• Poor performance status including two major system failures (including but not limited to cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular)
• Baseline creatinine greater than greater than or equal to 2.0 mg/dL
• Anatomy that does not allow for maintenance of at least one hypogastric artery
• Anatomy that does not allow primary or assisted patency of the left subclavian artery
• Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in a landing zone that expands beyond any limits of the previously placed graft material
• Obstructive stenting of any or all of the visceral vessels Or
• A patient that meets the criteria for inclusion into the primary study arm and:
• Would not be eligible for the primary study arm per a documented reason other than those outlined above, and
• Per the opinion of the Principal Investigator, with concurrence of the IRB, alternatives therapies are unsatisfactory and the probable risk of using the investigational device is no greater than the probable risk from the disease or condition. These will be determined by standard of care assessments of their disease/aneurysm morphology by the treating investigator.

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Thoracic
• Thoracoabdominal Aortic Aneurysm

Intervention

Device:
• Thoracoabdominal Aortic Aneurysm Repair
Thoracoabdominal aortic aneurysm repair

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 30 days.	30 days
Primary	Preliminary Effectiveness	Proportion of subjects treated with the device that achieve and maintain treatment success at 1 year.	1 year
Secondary	Secondary Safety Endpoint:Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 6 Months.	6 months
Secondary	Secondary Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 1 year.	1 year.
Secondary	Secondary Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 2 years.	2 years.
Secondary	Secondary Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 3 years.	3 years.
Secondary	Secondary Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 4 years.	4 years.
Secondary	Secondary Safety Endpoint: Freedom From Major Adverse Events	Freedom from major adverse events (MAE) at 5 years.	5 years.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 30 days as defined by aneurysm exclusion.	30 days.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 6 months as defined by aneurysm exclusion.	6 months.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 2 years as defined by aneurysm exclusion.	2 years.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 3 years as defined by aneurysm exclusion.	3 years.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 4 years as define by aneurysm exclusion.	4 years.
Secondary	Secondary Effectiveness Assessment	Proportion of subjects treated with the device that achieve and maintain treatment success at 5 years as define by aneurysm exclusion.	5 years.